Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT / 5:00 PM ET Today PLEASANTON, Calif. , Nov. 14, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE ), a pioneer in health technology, reported third quarter 2024 results and provided a business update.
The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17 th back-in-stock launch, bolstered by an enhanced product experience and improved operations across manufacturing, logistics and customer service. Securing FDA 510(k) clearance for the EvieMED Ring and pursuing initial business-to-business (B2B) commercial agreements across the healthcare sector.
Advancing cuffless blood pressure and noninvasive glucose monitoring clinical studies with Movano Health's proprietary and patented System-on-a-Chip (SoC). "We are pleased with our Evie Ring D2C performance and continue to be laser focused on improving the consumer experience, including the upcoming launch of our Android app, as we head into the holiday period in order to maximize our sales potential," said John Mastrototaro , President and CEO of Movano Health. "Additionally, we look forward to the successful completion of the 510(k) application review process of the EvieMED Ring and continue to focus on the game changin.